About this trial
A large body of evidence indicates numerous health benefits of physical activity, including prevention of cardiovascular disease (CVD), the leading cause of death in the US. This evidence has led to US Physical Activity Guidelines that recommend ≥150 min/week of moderate or ≥75 min/week of vigorous aerobic exercise (AE), plus resistance exercise (RE; such as weight lifting) on ≥2 days/week. To date, current research has mostly focused on AE, and we know a great deal about the dose-response relation between AE and health, resulting in clear and practical guidance to the public on the recommended "dose" in min/week. However, currently far less is known about the dose-response for RE: ≥2 days/week are recommended, but with no duration specified. Thus, this project aims to provide clarity on the dose relationship between RE and health. This project will significantly contribute to developing more effective CVD prevention approaches, advancing prescriptive intervention guidelines, by helping to fill the important gaps in knowledge on effective minimum dose, beneficial optimal dose, and safe maximum dose of RE for CVD prevention. Thus, advancing prescriptive intervention guidelines, and provide important insights for future science of physical activity and health.
Eligibility criteria
Qualifiers
Non-Smoker
Overweight or Obese: Body Mass Index 25-43 kg/m2
Inactive: not meeting the US resistance and aerobic exercise guidelines over the last 6 months
Walking <7,000 steps/day at baseline
Disqualifiers
Unstable coronary heart disease or heart failure
Uncontrolled arrhythmias or severe aortic stenosis
Acute myocarditis, endocarditis, or pericarditis
Cancer, requiring treatment in the past 5 years
Trial design
Treatments tested in this trial
- Aerobic exercise only
- 30 min of resistance exercise
- 60 min of resistance exercise
- 120 min of resistance exercise
Treatment groups
Sponsors and collaborators
University of Pittsburgh
Lead sponsor
University of California, Riverside
Collaborator
Iowa State University
Collaborator
Harvard School of Public Health (HSPH)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator